Kiora Pharmaceuticals, Inc. (KPRX) AI Stock Analysis

Kiora Pharmaceuticals, Inc. is an Encinitas, California-based clinical-stage specialty pharmaceutical company focusing on ophthalmic treatments. Its lead candidate, KIO-301, is in Phase 1 trials and uses a novel photoswitch mechanism aimed at restoring vision in patients with inherited and age-related degenerative retinal diseases. The company is also evaluating KIO-101 in Phase 2 trials for ocular manifestations of rheumatoid arthritis and non-infectious posterior uveitis. Additionally, its KIO-201 eye drop candidate is in Phase 3 trials for corneal wound repair after PRK surgery. Originally founded as Eyegate Pharmaceuticals in 1998, the firm was rebranded to Kiora Pharmaceuticals in November 2021.

Kiora has demonstrated significant historical revenue volatility. Revenue grew from $1.7M in FY2018 to $2.7M in FY2019 before dropping to $12,059 in FY2020 and remaining at $12,059 in FY2021, when net income was -$13.8M. In FY2024, revenue jumped to $16.0M, generating an operating margin of 28.2%, net income of $3.6M, and diluted EPS of $0.87. However, for the trailing twelve months ended June 30, 2026, revenue was $0, with both operating margin and profit margin at 0.0%, yielding an EPS of -$2.46. Return on equity stood at -56.4% and return on assets was -21.9%.

As of June 30, 2026, Kiora held $16.8M in cash and short-term investments against total debt of $333,022, resulting in net cash of $16.5M. Total assets stood at $23.8M, supported by shareholders' equity of $16.9M, yielding a debt-to-equity ratio of 0.02 and a current ratio of 8.97. In FY2025, capital expenditures totaled $110,789. The five-year change in share count was -51.2%.

At a market capitalization of $10.6M and an enterprise value of -$4.9M, Kiora trades at a forward P/E of 2.4x, well below the 17.3x forward P/E median of its US-listed Healthcare peers. Its price-to-sales multiple is 0.1x compared to the peer median of 4.1x, while its price-to-book ratio is 0.7x. The stock has delivered a 21.8% year-to-date return as of October 16, 2026, but its 1-year return of -11.1% and 5-year return of -99.7% lag the S&P 500 returns of 16.8% and 83.0%, respectively.

Wall Street coverage consists of 1 analyst with a Buy rating and zero Hold or Sell ratings. The mean price target is $12.00, representing a 400.0% premium over the last close of $2.40. For the fiscal year ending December 31, 2026, the consensus EPS estimate is -$1.67 on estimated revenue of $0. For the following fiscal year, 1 analyst projects an EPS of -$1.41 on $0 in revenue. Over the last four quarters, Kiora beat EPS estimates 3 times. The next earnings date is November 6, 2026.

This page is an AI-written research summary of Kiora Pharmaceuticals, Inc. (KPRX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: KPRX income statement, KPRX balance sheet, KPRX key metrics, KPRX analyst forecast, KPRX chart. See the KPRX stock overview for the latest quote and news.